Tanay Kumar Roy

https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
8 Feb 2024
Renata: Q2 FY24:: 440 bps OP/Sales rise and c13% fin exp spike flattens profit
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
5 Feb 2024
Square Pharmaceuticals: Q2 FY24: c14% sales growth mainly dampened by 410 bps GM fall
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
5 Feb 2024
Beximco Pharmaceuticals: Q2 FY24: Cons. NPAT up c16% yoy due to c10% sales rise and 270bps tax rate fall
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
5 Feb 2024
Marico Bangladesh: Q3 FY24: 795 bps GM rise due to sustained low copra prices drives NPAT by c13%
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
4 Feb 2024
IBN SINA Pharmaceutical: Q2 FY24: c36% sales growth drives c14% NPAT growth
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
19 Jan 2024
Regulator lifts floor price, excl. 35 companies; regular circuit breakers resume
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
31 Dec 2023
The Opportunist's Manifesto for 2024
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
13 Dec 2023
How did Bangladeshi pharmaceutical companies perform in Jul-Sep’23?
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
22 Nov 2023
IBN SINA Pharmaceutical: NPAT rose c13% yoy in Q1 FY24 driven by a c18% sales growth
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
20 Nov 2023
Square Pharmaceuticals: NPAT rose c9% yoy due to c15% conso. sales rise, 135bps GM rise, 157bps tax fall
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
14 Nov 2023
Olympic Industries: Q1 FY24: Margin improvement and lower opex-to-sales raised NPAT by c21% YoY
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
8 Nov 2023
Beximco Pharmaceuticals: Q1 FY24 Earnings Update: Consol. NPAT rose c7% driven by subsidiaries’ profits
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
2 Nov 2023
BRAC Bank: Q3'23: c36% YoY NPAT gr. driven by inv. inc, loan portfolio gr. and bKash’s NPAT
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
1 Nov 2023
LafargeHolcim: Q3'23: c41% NPAT growth driven by c12% sales rise and 107bps GM rise
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
31 Oct 2023
Reckitt Benckiser Bangladesh: Q3 CY23: NPAT rose c19% yoy driven by c9% sales growth and 925bps GM rise
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
29 Oct 2023
Walton Hi-Tech Industries: Q1'24 Earnings Update: 330bps GM rise and lower exchange loss turn NPAT positive
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
29 Oct 2023
Marico Bangladesh: Q2'24 Earnings Update: NPAT rose c20% yoy mainly driven by 520 bps GM expansion
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
25 Oct 2023
Beximco Pharmaceuticals: Earnings rose by c16% yoy in Q4 FY23 but fell by 10% yoy in FY23
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
23 Oct 2023
Square Pharmaceuticals: FY23 Earnings Update: 5% NPAT growth in FY23 is in line with expectations
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
12 Sep 2023
IDLC-SL September 2023 TOP PICKS
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
3 Aug 2023
Reckitt Benckiser Bangladesh: Flat NPAT growth in Q2 CY23 due to 454 bps opex/sales rise and 410 bps tax rise
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
3 Aug 2023
Unilever Consumer Care: NPAT fell c9% yoy driven by c9% revenue fall in Q2 CY23
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
28 Jul 2023
Marico Bangladesh: Q1'24: NPAT rose c29% yoy driven by 604 bps margin expansion, beats expectations
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
25 Jul 2023
LafargeHolcim: Q2 CY23: c39% NPAT growth driven by c34% revenue growth and 595bps GM expansion
https://cdn.tellimer.com/providers/rad-partner-badge-idlcpng.png
IDLC Securities
19 Jun 2023
IDLC-SL H1 FY24 MPS Review: Interest Rate Cap Lifted to Introduce Corridor

Tanay Kumar Roy
About Tanay Kumar Roy

Research Analyst @ IDLC Securities

Tanay Kumar Roy covers Pharmaceutical, Telecom and Consumer stocks. Before starting his career as a sell-side analyst, Tanay gathered experience as a buy-side analyst in LR Global BAMCO. He graduated from Institute of Business Administration (IBA), University of Dhaka.

Get in touch

Access to analysts is a Pro feature.